JPH02193915A - Medical cataplasm - Google Patents

Abstract

PURPOSE:To obtain a medical cataplasm capable of readily adhering to a human body and free from moving and squeezing by laminating plural tacky adhesive layers on a backing support while inserting an intermediate sheet having releasing property on the both surfaces and each containing a crosslinking reaction component in one of the tacky adhesive layers and crosslinking components in the remainder. CONSTITUTION:The first tacky adhesive layer 2 (e.g. polymer consisting of 82mol octyl acrylate, 8mol butyl methacrylate and 10mol methacrylic acid and having 460000 weight average molecular weight), and the second tacky adhesive layer 4 containing an intermediate sheet 3 having release property on the both surface and crosslinking component (e.g. zinc octylate) for the first tacky agent layer are successively laminated and further protecting sheet 5 is laminated thereon. The protecting sheet 5 having release property is released from the tacky adhesive layer 4 and the intermediate sheet 3 is released while putting the tacky adhesive layer 4 thereon and turned upside down and the tacky adhesive layer 4 is bonded to the tacky adhesive layer 2 and the intermediate sheet 3 is released the exposed surface of the tacky adhesive layer 4 is pressed and applied upon an appointed part of skin. A medicine is contained in at least one layer of tacky adhesive layers 2 and 4.

Description

DETAILED DESCRIPTION OF THE INVENTION (Field of Industrial Application) The present invention relates to a medical patch that is used by being applied to a predetermined location on human skin using the adhesive force of an adhesive.

(Prior Art) A medical patch having an adhesive layer may contain a drug that has a local medicinal effect on the skin or a drug that has a systemic effect through transdermal absorption. many.

In such medical patches, during application to the human body, in order to prevent oozing due to the flow phenomenon of the adhesive, misalignment of the entire application side, adhesive residue after peeling off the patch, etc., The adhesive layer is made to have crosslinking reactivity, and the cohesive force of the adhesive is increased by the crosslinking reaction.

In addition, we determine the combination of the adhesive composition and the drug by considering the interaction and compatibility between the adhesive composition and the medicinal drug, and we also provide auxiliary agents that promote the transfer and absorption of the drug into the human body. It is also being included.

(Problems to be Solved by the Invention) However, conventional adhesive patches have the following problems due to their single-layer adhesive layer.

■ At the initial stage of application, it is desirable for the adhesive layer to be in close contact with the skin immediately or in a short period of time.For this purpose, it is desirable that the adhesive layer be initially soft (low cohesive force state), and after application, it will adhere to the skin to some extent. The increased cohesive force ensures adhesion, and once stabilized, it prevents slippage and adhesive oozing, and also reduces pain when removing the patch and reduces adhesive residue. Although this is desirable, if the adhesive layer has crosslinking properties to prevent slippage and adhesive oozing, there is a problem with adhesion since the adhesive layer is already in a cohesive state from the beginning. When using a cross-linked curing type that gradually cross-links the adhesive, it is difficult to select the curing speed because the period of time until the application side is used is uncertain. In some cases, it may remain in a state where oozing occurs.

■ Changes in quality of the adhesive and/or drug due to interactions between the adhesive composition (particularly the cross-linking agent when it is included) and the drug, or between drugs, compatibility, etc., or decrease in the tackiness of the adhesive; In addition, the combination of the adhesive composition and the drug, as well as the combination of drugs with each other, must be determined in consideration of the transfer and release of the drug into the human body in the adhesive layer, which limits the type and amount of the drug used. However, it is difficult to provide a more desirable adhesive patch.

■ When the adhesive layer has crosslinking properties, components that react with each other are mixed in the same medium (solution, emulsion, etc.), so it is necessary to The crosslinking reaction may also proceed, making coating unstable or impossible. If the crosslinking reaction rate in the adhesive is slowed down in an attempt to solve this problem, the adhesive will change over time after it is commercialized, that is, after the adhesive patch is completed, and the product will lack stability.

Therefore, the present invention is designed to easily adhere to the human body at the beginning of application,
After application, the adhesive layer hardens appropriately to prevent slippage and adhesive oozing, and when removed, there is less pain and less adhesive residue.This is a medical patch that eliminates the problems with conventional adhesive patches as much as possible. The purpose is to provide a drug.

(Means for Solving the Problems) In order to solve the above-mentioned problems, the present inventor conducted intensive research and found that the adhesive layer is divided into a plurality of layers, these adhesive layers are isolated from each other during storage of the patch, and each A crosslinking reaction component that increases cohesive force due to a crosslinking reaction, a crosslinking component for causing a crosslinking reaction, a medicinal ingredient or a drug, etc. are separately contained in the adhesive layer,
The present invention was completed based on the discovery that it is sufficient to bond (laminate and adhere) these pressure-sensitive adhesive layers to each other during use.

That is, the present invention comprises a backing support and a plurality of adhesive layers sequentially laminated on the support, and a double-sided releasable intermediate sheet is disposed between the adjacent adhesive layers, and the adjacent adhesive layers are disposed between adjacent adhesive layers. The layers are separated from each other, and at least one of the plurality of adhesive layers contains a crosslinking component that increases cohesive force through a crosslinking reaction, and at least one of the remaining adhesive layers contains a crosslinking component. It contains
The present invention provides a medical patch characterized in that at least one of the plurality of adhesive layers contains a medicinal drug.

The adhesive layer may have three or more layers, but in one embodiment, two adhesive layers are provided, and the adhesive layer that is in contact with the backing support has a crosslinking reaction component. , and the other pressure-sensitive adhesive layer contains a crosslinking component.

A releasable protective sheet can be laminated on the outer surface of the outermost adhesive layer among the plurality of adhesive layers for preservation and the like.

In addition, while being sandwiched between the folded base sheet from above and below, the outer surface of the backing support is temporarily attached to one inner surface of the base sheet, and the adhesive of the outermost layer is attached to the other inner surface of the base sheet. The outer surfaces of the agent layers may be temporarily attached.

As for the drug-containing aspect of the adhesive layer, it is conceivable that one adhesive layer contains a necessary amount of the drug, but at least two of the adhesive layers may contain a drug having at least one different component or concentration. may be contained respectively.

(Function) According to the medical patch of the present invention, the adhesive layers are separated from each other by the double-sided releasable intermediate sheet during storage of the patch. In use, the intermediate sheet between adjacent adhesive layers is removed, the exposed adhesive layer surfaces are adhered to each other in a predetermined combination, and then the outermost adhesive layer surface is applied to a predetermined location on human skin. It will be worn. During the application, the adhesive layer containing the crosslinking component and the adhesive layer containing the crosslinking component come into contact with each other, a crosslinking reaction progresses, and a suitable cohesive force is generated in the adhesive.

(Example) Embodiments of the present invention will be described below with reference to the drawings.

1 to 3 show one embodiment of the present invention. First, the general structure and method of use of this medical patch will be described. This patch includes a patch-side original body 10 made of a backing support 1 and an adhesive layer 2 laminated thereon. Further, a double-sided releasable intermediate sheet 3 and another adhesive layer 4 are sequentially laminated on the adhesive layer 2 of this original body 10. Adhesive layers 2 and 4 are separated from each other by sheet 3. The adhesive layer 4 is further covered with a releasable protective sheet 5 having releasable properties on the surface facing the core layer.

Now, the mutual adhesion force (force required for peeling) between each layer is expressed as F, F between layers 1 and 2 is Fl-2, F between layers 2 and 3 is F2-3, and layer 3 is F1-2. When F between layers 4 and 5 is F3-4, and F4-5 is between layers 4 and 5, mutual adhesion force F
4-5 is set smaller than any other F.

The procedure for using the patch shown in FIG. 1 is as shown in FIGS. 2-1 to 2-4.

That is, F4-5< (Fl-2, F2-3, F3-
From the relationship 4), the surface releasable protective sheet 5 is first peeled off from the adhesive layer 4 (see Figure 2-1).

In the second step, the double-sided releasable intermediate sheet 3 is peeled off from the adhesive layer 2 with the adhesive layer 4 still on it (see Figure 2-2).

Next, the sheet 3 carrying the adhesive layer 4 is turned upside down, and the adhesive layer 4 is bonded to the adhesive layer 2 of the application-side prototype body 10 to form the final completed body 20 to be applied to human skin. (
(See Figure 2-3).

Thereafter, the intermediate sheet 3 is peeled off from the adhesive layer 4 (see Figures 2-4), and the exposed surface of the adhesive layer 4 is pressed against a predetermined location on the human skin as shown in Figure 3. In this way, the completed body 20 is pasted and fixed at a predetermined location on the skin TfHD.

In addition, when F3-4 is smaller than any other F, the completed body 20 is obtained by the procedure shown in FIGS. 4-1 to 4-4.

That is, first, the interface between the intermediate sheet 3 and the adhesive N4 is separated (see FIG. 4-1). Next, the intermediate sheet 3 is peeled off from the adhesive layer 2 of the original body 10 (see FIG. 4-2). The adhesive layer 4 is then bonded to the adhesive layer 2 to form the final product 20 to be applied to human skin (see Figure 4-3). Thereafter, the protective sheet 5 is peeled off from the adhesive layer 4, and the isolated finished product 2o is applied to a predetermined location on the human skin in the same manner as shown in FIG.

The materials of each part in the embodiment shown in FIGS. 1 to 3 are as follows.

(2) Backing support 1 A 60 μm thick non-porous film made of ethylene-vinyl acetate copolymer resin (EVA resin) with a vinyl acetate content of 20%, the surface of which was subjected to corona discharge treatment.

■ First adhesive layer 2 100 parts by weight of an adhesive base polymer with a weight average molecular weight of approximately 460,000, consisting of a ratio of 82 moles of octyl acrylate, 8 moles of butyl methacrylate, and 10 moles of methacrylic acid, is mixed with fluorosinol as a medicinal ingredient. It consists of a composition containing approximately 0.8% by weight of ronacetonide (steroid),
The thickness is approximately 40 μm.

■ Intermediate sheet 3 Polyoctadecyl ethylene urea (this product contains 1 octadecyl isocyanate per 1 ethyleneimine equivalent of polyethyleneimine) on both sides of a 50 μm thick PET film.
．． 1 equivalent was subjected to an addition reaction in toluene below its boiling point, and after the reaction, it was precipitated with ethanol.) was coated uniformly at a concentration of 0.04 g per 1 M. (made by gravure roll from toluene solution).

■ Second adhesive layer 4 Octyl acrylate 60 mol% to Butyl methacrylate 4
0.4% of prednisolone as a medicinal ingredient and octyl as a crosslinking component or crosslinking agent for the first adhesive layer 2 with respect to 100 parts by weight of the adhesive basic polymer having a weight average molecular weight of approximately 680,000 and comprising a ratio of 0 mol %. It consists of a composition in which 15 parts of zinc oxide is uniformly dispersed and dissolved, and the thickness is about 20 μm.

■ Peelable protective sheet 5 Consists of silicone release paper coated with release silicone on the polylaminated surface of kraft paper, one side of which has been polylaminated. However, kraft base paper basis weight: 60g/rd, polylaminate thickness: 6±Lum, silicone type: Shin-Etsu Chemical KS-
772, silicone coating amount: 0.1 g/rrf.

In the example patch shown in FIG. 1 having the above configuration, the mutual adhesion force F4-5 (=force required for peeling) between the second adhesive layer 4 and the protective sheet 5 is the same as that between the intermediate sheet 3 and the second adhesive layer. Mutual adhesion force F3-4 between agent layers 4, intermediate sheet 3
and the mutual adhesion force F2-3 between the first adhesive layer 2 and the mutual adhesion force F1-2 between the backing support 1 and the first adhesive layer 2.

Therefore, as described above, it is used through the steps shown in FIGS. 2-1 to 2-4.

According to this embodiment, after the adhesive layers 2 and 4 are bonded together, zinc octylate in the adhesive layer 4 migrates into the first adhesive layer 2, and the main polymer composition of the layer 2 is The internal cohesive force increases during application due to relatively rapid recombination and ionic crosslinking between the carboxyl groups and the zinc ions. For this reason, the adhesive is very flexible and adheres to the skin immediately after application, and the cohesive force of the first adhesive layer 2 increases gradually during application (with the help of body temperature). This prevents the finished product 20 from shifting and the adhesive from seeping out, and when it is finally removed, the adhesive has just the right amount of cohesive strength to prevent the adhesive from remaining on the skin or causing pain due to excessive adhesive strength. do not have.

Furthermore, in this example, since the second adhesive layer 4 also contains prednisolone, which has the same medicinal properties and takes into account the quick-acting aspect, it can exhibit almost stable medicinal efficacy over a long period of time immediately after application. As the first adhesive layer 2 is crosslinked, its drug release ability is also improved, and as a result, the total drug utilization rate can be increased. Even if the adhesive layer is composed of only one of them and has the same thickness, for example, the adhesive strength may be too strong (and too soft at the same time) or insufficient, or it may not last for a long time immediately after application (for example, It is not possible to overcome the drawbacks such as difficulty in obtaining stable drug efficacy (=drug release properties) until after 24 hours.

Furthermore, even if the same two-layer adhesive structure is used, if there is no crosslinking component such as an ionic crosslinking agent for carboxyl groups such as zinc octylate in the second adhesive layer 4, the first adhesive layer Layer 2 remains too soft even after application, so it tends to slip or ooze out during application, and the drug release properties (
= duration of drug efficacy) will also be lower.

Next, another embodiment will be described with reference to FIG. 5 and subsequent figures. FIG. 5 shows a side view of this other embodiment, with the thickness of each part slightly enlarged.

This embodiment also includes an application-side original body 10 consisting of a backing support 1 and a first adhesive layer 2 laminated thereon.

A second adhesive layer 4 is laminated on the adhesive surface of the adhesive layer 2 via an intermediate sheet 3 that is removable on both sides.

These original body 10, intermediate sheet 3, and second adhesive layer 4 are sandwiched from above and below by a base sheet 6 that is folded in half along a fold line P and can be opened and closed. One inner surface S1 of the base sheet 6 is temporarily attached to the outer surface of the backing support 1 with a suitable adhesive, and the other inner surface S2 of the base sheet 6 is temporarily attached to the adhesive layer 4 in a releasable manner.

Here, the mutual adhesion force (force required for peeling) between each layer is represented by F, and F-t-F l between the base sheet 6 and the backing support 1
-6, F between backing support 1 and adhesive layer 2 is Fl-2
, F between adhesive layer 2 and intermediate sheet 3 is F2-3, F between intermediate sheet 3 and adhesive layer 4 is F3-4, F between adhesive layer 4 and base sheet 6 Assuming that F4-6 is F4-6, in this embodiment, the mutual adhesion force F3-4 is set to be the smallest than the other Fs.

The procedure for using the patch shown in Figure 5 is as shown in Figures 6-1 to 6-4.
As shown in the figure.

First, the base sheet 6 is opened left and right. Then, since the mutual adhesive force F3-4 is smaller than the other mutual adhesive forces F, the interface between the intermediate sheet 3 and the adhesive layer 4 is separated first, and the 6th-
As shown in FIG. 1, the base sheet 6 is opened left and right. In this state, the patch layer form 10 and the intermediate sheet 3 (on the inner surface S1 of the base sheet 6) and the second adhesive layer 4 are located on the inner surface S2 of the base sheet 6.

Next, the intermediate sheet 3 is peeled off from the original body 10 (see Figure 6-2), and then the base sheet 6 is folded in half again along the fold line P, and the first and second adhesive layers 2 and 4 are bonded together. , lightly press the base sheet 6 from above and below. The final product 20 to be applied to human skin is thus formed (see Figure 6-3).

The adhesive layers 2 and 4 are bonded to each other by folding the base sheet 6 along the fold line P, since these adhesive layers 2 and 4 are arranged in symmetrical positions with the fold line P of the base sheet 6 as the border. It can be joined and bonded extremely easily just by folding it in half.

After that, as shown in Fig. 6-4, the base sheet 6 is opened left and right again, and the completed body 20 is peeled off from the base sheet 6.
The exposed surface of the adhesive layer 4 can be pressed to a predetermined location on the human skin in the same manner as shown in FIG. 3, and the finished product 20 can be attached thereto.

Note that when the mutual adhesive force F2-3 between the first adhesive layer 2 and the intermediate sheet 3 is the smallest than the other F, the seventh-
The processing is performed as shown in Figures 1 to 7-3. That is, when the base sheet 6 is first opened to the left and right, the layers 2 and 3 are separated at the interface, resulting in the state shown in FIG. 7-1, and then the intermediate sheet 3 is peeled off from the second adhesive layer 4. (7th
-Refer to Figure 2) Fold the base sheet 6 in half again, and
and 4 can be joined together (see Figure 7-3).
. Thereafter, processing may be performed in the same manner as shown in FIG. 6-4.

Now, the materials of each part of the adhesive patch shown in FIGS. 5 to 6-4 are as follows.

■ Backing support I It consists of a 110 μm thick film (50% tensile modulus of about 50 kg/cd) of internally plasticized polyvinyl chloride (Nismezoica V: Sekisui Chemical), one side of which is provided with an adhesive layer. side) is pre-coated with an anchor primer, and the primer is a mixture of natural rubber latex and nitrile rubber latex (budadiene to acrylonitrile = 65 to 35) in a solids ratio of 30 to 7°. The coating is applied so that the thickness after drying is 8±2 μm.

■ First adhesive N2 50 moles of 2-ethylhexyl acrylate to 20 moles of butyl acrylate to 30 moles of butyl methacrylate to 1.6-
For every 100 parts by weight of an adhesive base polymer consisting of 0.02 mol of hexane gelicol dimethacrylate and having a weight average molecular weight of less than about 720,000, 1 part of pentatritrithritol tetranitrate as a drug, and further 2 1. As a supplementary crosslinking agent for the adhesive layer. 4. It has a composition in which 10 parts of an adduct of 1 mole of butylene glycol to 2 moles of hexamethylene diisocyanate and 5 parts of dibutyltin dioctoate as a crosslinking accelerator are uniformly dissolved,
Its thickness is approximately 40 μm.

■ Double-sided releasable intermediate sheet 3 Lightly releasable silicone release agent (mainly Shin-Etsu Silicone KS-772) was coated on both sides of a 50 μIn thick PET film so that the thickness was 0.1 g/rd, and baked. It has been processed.

■ Second adhesive layer 4 A liquid polymer (manufactured by Idemitsu Petrochemical Co., Ltd., polybdR-45D) having a polybutadiene skeleton, 1.5% by weight of terminal OH groups, and an average molecular weight of 2800, which is liquid at room temperature. An adduct of the same polymer and tolylene diisocyanate (however, the ratio is 1:2 in terms of 10H groups to -NCO groups: trade name polybd HTP 9/manufactured by Idemitsu Oil Chemical Co., Ltd.) was mixed at a weight ratio of 88:12. Then, 0.002 weight of dibutyltin diacetate as a crosslinking reaction catalyst and 4 parts of isosorbite dinitrate as a chemical were added and mixed, and this was made into a layer with a thickness of about 20 μm. This is done to an extent that cohesive failure does not occur during the pasting process.

■ Base sheet 6 It is basically made of PET film with a thickness of 70 μm, and a shallow notch is added in a straight line in the center on one side, which is used as the fold line P. One part of the inner surface S2 on the surface is coated with one part of the same release agent as that used for the intermediate sheet 3 in the embodiment shown in FIG.
On the other inner surface S1, a mixture of synthetic polyisoprene, styrene/isoprene/styrene block copolymer, and polyterpene tackifier (softening point: 80°C) was applied in a 50:50:20 ratio. A slightly adhesive layer with a thickness of 10 μm consisting of a weight ratio of is applied over the majority of the respective area (larger area than layers 1 and 4). Then, the surface S2 of the base sheet 6 and the adhesive layer 4 are in such a relationship that the fold line P is exactly the axis of symmetry, and the surface S1 of the base sheet 6 and the backing support pair 1 are overlapped, and the fold line is It is folded in half with P serving as the folding ridgeline, and thus a patch having the structure shown in FIG. 5 is obtained.

In this example, the magnitude relationship of the adhesion force F at the interface between each layer described above is: F1-6>F4-6>F2-3>F
It is 3-4. However, Fl-2 is much larger than the other F's.

Therefore, the mode of use is as shown in FIGS. 6-1 to 6-4 described above.

In this example, since the adhesive layer 4 has not yet completely improved its cohesive strength, the core layer is soft, and when it is applied, it is well moistened to the skin and quickly reaches a state of adhesion, and is then bonded. The missing crosslinking agent component (adduct of 1,4-butylene glycol and hexamethylene diisocyanate) and crosslinking catalyst (dibutyltin dioctoate) are present in adhesive layer 2 to adhesive layer 4 during application. Due to the accelerating action of moisture absorbed from the skin, etc., it gradually migrates into the adhesive layer 4, and at the same time a crosslinking reaction is achieved, which takes about the same amount of time (12 to 48 hours) as the purpose of application is achieved.
Afterwards, it has reached a sufficient cohesive strength, so there is no adhesive residue or severe pain when it is removed.

In addition, two types of drugs with the same medicinal properties but with different diffusion and migration behavior in the adhesive are originally included in each adhesive layer, so the drug remains almost constant for a long time immediately after application. It has the advantage of maintaining similar medicinal efficacy.

As can be seen from this example description, the patch of the present invention is
It is particularly suitable as a long-term application type patch that requires application for several hours or more.

Although the planar shape of each part was not specifically explained in any of the above embodiments, the shape may be any shape such as a perfect circle, an ellipse, a semicircle, a rectangle, or a square. Regarding the planar size of each part,
Although various selections can be made, the intermediate sheet 3 can be used for the patch original form pair 10.
It is preferable that the protection sheet 5 covers these surfaces in a larger area than both the adhesive layer 4 and the adhesive layer 4, and it is also preferable that the protective sheet 5 covers these surfaces in a larger area than the adhesive layer 4.

It is convenient for use that the base sheet 6 has a size such that its periphery protrudes outward from the original body 10 and the adhesive layer 4 in the state of No. 9E.

The present invention is not limited to the above embodiments, and can be implemented in various other ways. For example, it is not necessary to limit to which of the adhesive layers 2 and 4 the crosslinking agent is applied and which of the non-crosslinked polymer is applied.
It goes without saying that the patch can be selected freely depending on the purpose of the patch, the drug used, the required performance on the patch side, etc.

(Effects of the Invention) According to the present invention, a patch having the following advantages can be provided.

(2) Since the two (or more) adhesive layers are isolated until just before use, these adhesive layers can be stored for a long time without any mutual deterioration.

- Since the crosslinking agent and the crosslinkable polymer or the polymers that react with each other and crosslink each other are isolated during storage, their softness is maintained and the immediate adhesion immediately after application is not impaired.

■ Cohesive strength due to cross-linking begins to improve after application, and cross-linking has progressed appropriately by the time the adhesive is removed after the scheduled application time has elapsed, so there is less slippage and oozing than when using non-cross-linked adhesives, and it is easy to peel off. It is also less painful.

(2) During manufacturing, the components involved in crosslinking are applied separately, so the adhesive does not gel before or during coating, and therefore manufacturing is easy. Further, a crosslinking system having a high crosslinking rate can be used.

■ If the agent used is not suitable for long-term coexistence, such as because it reacts with one of the crosslinking components, the agent can be incorporated into the other adhesive layer that does not contain the crosslinking component. The range of drugs that can be used is expanded.

(2) If the physical properties of the adhesive containing the agent change, such as softening or hardening, depending on the agent used, the disadvantages can be adjusted and improved by the crosslinking mechanism of the two-layer adhesive.

(2) By incorporating the drug in two (or more) layers of adhesive at varying concentrations, it is easier to provide a dosage form suitable for sustained release or immediate release.

(2) If an adhesive suitable for encapsulating the target drug is unfortunately not suitable for application to the skin, the adhesive for the second layer can be selected to be suitable for application to the skin.

■ If you want to include two (or more) types of drugs, but unfortunately they can coexist in the same adhesive composition, or if they coexist, they will have an adverse effect on each other, then select appropriate adhesive compositions for each. It is possible to apply it in two or more layers.

[Phase] For patches that use hydrophilic (or water-soluble) adhesives, such as poultices, a large amount of moisture is absorbed from subcutaneously during application, and as a result, the adhesive softens indefinitely during application. However, in this respect, the adhesive of the present invention improves cohesive force as crosslinking progresses, so this drawback can be prevented.

■ It is easy to use since the adhesive layers are separated from each other by an intermediate sheet, and the structure is simple and can be provided at low cost.

Figures 1 to 3 show an embodiment of the present invention, with Figure 1 being an overall side view showing the thickness of each part enlarged, and Figure 2-1.
2 to 4 are explanatory views of the procedure for using the adhesive patch shown in FIG. 1, and FIG. 3 is an explanatory view of the state of use. Figures 4-1 to 4-4 show other embodiments, and are diagrams illustrating the procedure for using the adhesive patch shown in Figure 1 in which each layer has a slight degree of mutual adhesion. It is. Figures 5 to 6-4 show still other embodiments, Figure 5 is an overall side view showing the thickness of each part slightly enlarged, and Figures 6-1 to 6-4 are respectively FIG. 2 is an explanatory diagram of the procedure for using the patch shown in the figure. Figures 7-1 to 7-3 show still other embodiments, and are diagrams illustrating the procedure for using the adhesive patch shown in Figure 5, which has some degree of mutual adhesion between the layers. 1... Backing support body, 2... First adhesive layer,
10...Pasting side original form, 3...Intermediate sheet, 4...
- Second adhesive layer, 5... Protective sheet, 6... Base sheet, Sl, S2... Base sheet inner surface, P... Crease line, 20... Completed product that can be pasted.

that's all

Claims (1)

[Claims] 1. A backing support and a plurality of adhesive layers sequentially laminated on the support, and a double-sided releasable intermediate sheet is disposed between the adjacent adhesive layers. The adhesive layers are separated from each other, and at least one of the plurality of adhesive layers contains a crosslinking reaction component that increases cohesive force through a crosslinking reaction, and at least one of the remaining adhesive layers contains a crosslinking component. A medical patch, characterized in that the adhesive layer contains a chemical component, and at least one of the plurality of adhesive layers contains a medicinal drug. 2. The outer surface of the backing support is temporarily attached to one inner surface of the base sheet while being sandwiched between the folded base sheet from above and below, and the outermost layer of the backing support is temporarily attached to the other inner surface of the base sheet. The medical patch according to claim 1, wherein the outer surfaces of the adhesive layers are temporarily attached.